对于治疗多发性骨髓瘤和淋巴瘤的赛美西多米德,C4 Therapeutics报告了有前途的第一阶段结果. C4 Therapeutics reports promising Phase 1 results for cemsidomide in treating multiple myeloma and lymphoma.

C4 治疗学显示,Cemsidomide的第一阶段数据很有希望,Cemsidomide是一种治疗多种骨髓瘤和非Hodgkin淋巴瘤的治疗方法。 C4 Therapeutics has shown promising Phase 1 data for cemsidomide, a treatment for multiple myeloma and non-Hodgkin's lymphoma. 与 dexamethasone 相结合,最高剂量的cemsidomide达到36%的总体回复率和45%的临床福利率。 When combined with dexamethasone, the highest dose of cemsidomide achieved a 36% overall response rate and a 45% clinical benefit rate. 这种可降解IKZF1/3蛋白质的药物是经过良好修饰的,可成为这些癌症的关键治疗方法。 The drug, which degrades IKZF1/3 proteins, is well-tolerated and could become a key therapy for these cancers.

文章

The Manila Times

TMCnet

www.einpresswire.com

-- 显示更少 --

相关故事